MovDisordV3, PascalFrancis, Corpus, bibRecord, 000E93

Adherence to Antiparkinson Medication in a Multicenter European Study

Identifieur interne : 000E93 ( PascalFrancis/Corpus ); précédent : 000E92; suivant : 000E94

Adherence to Antiparkinson Medication in a Multicenter European Study

Auteurs : Donald Grosset ; Angelo Antonini ; Margherita Canesi ; Gianni Pezzoli ; Andrew Lees ; Karen Shaw ; Esther Cubo ; Pablo Martinez-Martin ; Olivier Rascol ; Laurence Negre-Pages ; Ana Senard ; Johannes Schwarz ; Karl Strecker ; Heinz Reichmann ; Alexander Storch ; Matthias Löhle ; Fabrizio Stocchi ; Katherine Grosset

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0223199

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Chimiothérapie, Etude multicentrique.

English descriptors

KwdEn :
- Chemotherapy, Multicenter study, Nervous system diseases, Parkinson disease.

Abstract

Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine-taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6-100), days adherence (correct dose days) was 86.2% (IQ 61.1-96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3-56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0-33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205-670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20-40), versus those with satisfactory adherence at 19 (IQ 13-26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Adherence to Antiparkinson Medication in a Multicenter European Study`
A11	`01`	`1`		`@1 GROSSET (Donald)`
A11	`02`	`1`		`@1 ANTONINI (Angelo)`
A11	`03`	`1`		`@1 CANESI (Margherita)`
A11	`04`	`1`		`@1 PEZZOLI (Gianni)`
A11	`05`	`1`		`@1 LEES (Andrew)`
A11	`06`	`1`		`@1 SHAW (Karen)`
A11	`07`	`1`		`@1 CUBO (Esther)`
A11	`08`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`09`	`1`		`@1 RASCOL (Olivier)`
A11	`10`	`1`		`@1 NEGRE-PAGES (Laurence)`
A11	`11`	`1`		`@1 SENARD (Ana)`
A11	`12`	`1`		`@1 SCHWARZ (Johannes)`
A11	`13`	`1`		`@1 STRECKER (Karl)`
A11	`14`	`1`		`@1 REICHMANN (Heinz)`
A11	`15`	`1`		`@1 STORCH (Alexander)`
A11	`16`	`1`		`@1 LÖHLE (Matthias)`
A11	`17`	`1`		`@1 STOCCHI (Fabrizio)`
A11	`18`	`1`		`@1 GROSSET (Katherine)`
A14	`01`			`@1 Institute of Neurological Sciences, Southern General Hospital @2 Glasgow @3 GBR @Z 1 aut. @Z 18 aut.`
A14	`02`			`@1 Parkinson Institute Milan @3 ITA @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 University College London @3 GBR @Z 5 aut. @Z 6 aut.`
A14	`04`			`@1 Carlos III Institute for Health @2 Madrid @3 ESP @Z 7 aut. @Z 8 aut.`
A14	`05`			`@1 Toulouse University Hospital @2 Toulouse @3 FRA @Z 9 aut. @Z 10 aut. @Z 11 aut.`
A14	`06`			`@1 University of Leipzig @3 DEU @Z 12 aut. @Z 13 aut.`
A14	`07`			`@1 Technical University of Dresden @3 DEU @Z 14 aut. @Z 15 aut. @Z 16 aut.`
A14	`08`			`@1 IRCCS San Raffaele Pisana @2 Rome @3 ITA @Z 17 aut.`
A20				`@1 826-832`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186181820050`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 09-0223199`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine-taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6-100), days adherence (correct dose days) was 86.2% (IQ 61.1-96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3-56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0-33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205-670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20-40), versus those with satisfactory adherence at 19 (IQ 13-26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 09`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 09`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 09`
C03	`04`	`X`	`FRE`	`@0 Etude multicentrique @5 10`
C03	`04`	`X`	`ENG`	`@0 Multicenter study @5 10`
C03	`04`	`X`	`SPA`	`@0 Estudio multicéntrico @5 10`
C07	`01`	`X`	`FRE`	`@0 Traitement`
C07	`01`	`X`	`ENG`	`@0 Treatment`
C07	`01`	`X`	`SPA`	`@0 Tratamiento`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 166`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0223199 INIST
ET :	Adherence to Antiparkinson Medication in a Multicenter European Study
AU :	GROSSET (Donald); ANTONINI (Angelo); CANESI (Margherita); PEZZOLI (Gianni); LEES (Andrew); SHAW (Karen); CUBO (Esther); MARTINEZ-MARTIN (Pablo); RASCOL (Olivier); NEGRE-PAGES (Laurence); SENARD (Ana); SCHWARZ (Johannes); STRECKER (Karl); REICHMANN (Heinz); STORCH (Alexander); LÖHLE (Matthias); STOCCHI (Fabrizio); GROSSET (Katherine)
AF :	Institute of Neurological Sciences, Southern General Hospital/Glasgow/Royaume-Uni (1 aut., 18 aut.); Parkinson Institute Milan/Italie (2 aut., 3 aut., 4 aut.); University College London/Royaume-Uni (5 aut., 6 aut.); Carlos III Institute for Health/Madrid/Espagne (7 aut., 8 aut.); Toulouse University Hospital/Toulouse/France (9 aut., 10 aut., 11 aut.); University of Leipzig/Allemagne (12 aut., 13 aut.); Technical University of Dresden/Allemagne (14 aut., 15 aut., 16 aut.); IRCCS San Raffaele Pisana/Rome/Italie (17 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 6; Pp. 826-832; Bibl. 20 ref.
LA :	Anglais
EA :	Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine-taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6-100), days adherence (correct dose days) was 86.2% (IQ 61.1-96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3-56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0-33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205-670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20-40), versus those with satisfactory adherence at 19 (IQ 13-26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease.
CC :	002B17; 002B17F
FD :	Maladie de Parkinson; Pathologie du système nerveux; Chimiothérapie; Etude multicentrique
FG :	Traitement; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Chemotherapy; Multicenter study
EG :	Treatment; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Quimioterapia; Estudio multicéntrico
LO :	INIST-20953.354000186181820050
ID :	09-0223199

Links to Exploration step

Pascal:09-0223199

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Adherence to Antiparkinson Medication in a Multicenter European Study</title>
<author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation><inist:fA14 i1="03"><s1>University College London</s1>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shaw, Karen" sort="Shaw, Karen" uniqKey="Shaw K" first="Karen" last="Shaw">Karen Shaw</name>
<affiliation><inist:fA14 i1="03"><s1>University College London</s1>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name>
<affiliation><inist:fA14 i1="04"><s1>Carlos III Institute for Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="04"><s1>Carlos III Institute for Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name>
<affiliation><inist:fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Senard, Ana" sort="Senard, Ana" uniqKey="Senard A" first="Ana" last="Senard">Ana Senard</name>
<affiliation><inist:fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
<affiliation><inist:fA14 i1="06"><s1>University of Leipzig</s1>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strecker, Karl" sort="Strecker, Karl" uniqKey="Strecker K" first="Karl" last="Strecker">Karl Strecker</name>
<affiliation><inist:fA14 i1="06"><s1>University of Leipzig</s1>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name>
<affiliation><inist:fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name>
<affiliation><inist:fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name>
<affiliation><inist:fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><inist:fA14 i1="08"><s1>IRCCS San Raffaele Pisana</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0223199</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0223199 INIST</idno>
<idno type="RBID">Pascal:09-0223199</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E93</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Adherence to Antiparkinson Medication in a Multicenter European Study</title>
<author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation><inist:fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation><inist:fA14 i1="03"><s1>University College London</s1>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shaw, Karen" sort="Shaw, Karen" uniqKey="Shaw K" first="Karen" last="Shaw">Karen Shaw</name>
<affiliation><inist:fA14 i1="03"><s1>University College London</s1>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name>
<affiliation><inist:fA14 i1="04"><s1>Carlos III Institute for Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="04"><s1>Carlos III Institute for Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name>
<affiliation><inist:fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Senard, Ana" sort="Senard, Ana" uniqKey="Senard A" first="Ana" last="Senard">Ana Senard</name>
<affiliation><inist:fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
<affiliation><inist:fA14 i1="06"><s1>University of Leipzig</s1>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strecker, Karl" sort="Strecker, Karl" uniqKey="Strecker K" first="Karl" last="Strecker">Karl Strecker</name>
<affiliation><inist:fA14 i1="06"><s1>University of Leipzig</s1>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name>
<affiliation><inist:fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name>
<affiliation><inist:fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name>
<affiliation><inist:fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><inist:fA14 i1="08"><s1>IRCCS San Raffaele Pisana</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Multicenter study</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Chimiothérapie</term>
<term>Etude multicentrique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine-taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6-100), days adherence (correct dose days) was 86.2% (IQ 61.1-96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3-56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0-33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205-670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20-40), versus those with satisfactory adherence at 19 (IQ 13-26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Adherence to Antiparkinson Medication in a Multicenter European Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GROSSET (Donald)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ANTONINI (Angelo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CANESI (Margherita)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PEZZOLI (Gianni)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LEES (Andrew)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SHAW (Karen)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CUBO (Esther)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>NEGRE-PAGES (Laurence)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SENARD (Ana)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SCHWARZ (Johannes)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>STRECKER (Karl)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>REICHMANN (Heinz)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>STORCH (Alexander)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>LÖHLE (Matthias)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>STOCCHI (Fabrizio)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>GROSSET (Katherine)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Parkinson Institute Milan</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University College London</s1>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Carlos III Institute for Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>University of Leipzig</s1>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Technical University of Dresden</s1>
<s3>DEU</s3>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>IRCCS San Raffaele Pisana</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA20><s1>826-832</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186181820050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0223199</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine-taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6-100), days adherence (correct dose days) was 86.2% (IQ 61.1-96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3-56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0-33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205-670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20-40), versus those with satisfactory adherence at 19 (IQ 13-26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>166</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0223199 INIST</NO>
<ET>Adherence to Antiparkinson Medication in a Multicenter European Study</ET>
<AU>GROSSET (Donald); ANTONINI (Angelo); CANESI (Margherita); PEZZOLI (Gianni); LEES (Andrew); SHAW (Karen); CUBO (Esther); MARTINEZ-MARTIN (Pablo); RASCOL (Olivier); NEGRE-PAGES (Laurence); SENARD (Ana); SCHWARZ (Johannes); STRECKER (Karl); REICHMANN (Heinz); STORCH (Alexander); LÖHLE (Matthias); STOCCHI (Fabrizio); GROSSET (Katherine)</AU>
<AF>Institute of Neurological Sciences, Southern General Hospital/Glasgow/Royaume-Uni (1 aut., 18 aut.); Parkinson Institute Milan/Italie (2 aut., 3 aut., 4 aut.); University College London/Royaume-Uni (5 aut., 6 aut.); Carlos III Institute for Health/Madrid/Espagne (7 aut., 8 aut.); Toulouse University Hospital/Toulouse/France (9 aut., 10 aut., 11 aut.); University of Leipzig/Allemagne (12 aut., 13 aut.); Technical University of Dresden/Allemagne (14 aut., 15 aut., 16 aut.); IRCCS San Raffaele Pisana/Rome/Italie (17 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 6; Pp. 826-832; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<EA>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine-taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6-100), days adherence (correct dose days) was 86.2% (IQ 61.1-96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3-56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0-33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205-670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20-40), versus those with satisfactory adherence at 19 (IQ 13-26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease.</EA>
<CC>002B17; 002B17F</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Chimiothérapie; Etude multicentrique</FD>
<FG>Traitement; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Chemotherapy; Multicenter study</ED>
<EG>Treatment; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Quimioterapia; Estudio multicéntrico</SD>
<LO>INIST-20953.354000186181820050</LO>
<ID>09-0223199</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E93 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E93 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0223199
   |texte=   Adherence to Antiparkinson Medication in a Multicenter European Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Adherence to Antiparkinson Medication in a Multicenter European Study

Adherence to Antiparkinson Medication in a Multicenter European Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri